Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: A report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation

European Journal of Cancer

Volumn 50, Issue 2, 2014, Pages 411-417

  Giebel, Sebastian ^a   Labopin, Myriam ^b,c,d   Gorin, Norbert Claude ^b,c,d   Caillot, Denis ^e   Leguay, Thibaut ^f   Schaap, Nicolaas ^g   Michallet, Mauricette ^h   Dombret, Herve ⁱ   Mohty, Mohamad ^b,c,d  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b HÔPITAL SAINT ANTOINE   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^e HÔPITAL DU BOCAGE   (France)

^f HAUT LÉVÊQUE HOSPITAL   (France)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h CENTRE HOSPITALIER LYON SUD   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

Author keywords

Acute lymphoblastic leukaemia; Autologous stem cell transplantation; Leukaemia free survival; Philadelphia positive; Tyrosine kinase inhibitors

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER MORTALITY; FEMALE; HUMAN; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; OVERALL SURVIVAL; PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84891832641     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.08.027     Document Type: Article

References (23)

1. H. Dombret, J. Gabert, and J.M. Boiron et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia - results of the prospective multicenter LALA-94 trial Blood 100 2002 2357 2366
2. A. Wrzesień-Kuś, T. Robak, and A. Pluta et al. Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR-ABL - positive acute lymphoblastic leukemia-retrospective analysis of Polish Adult Leukemia Group (PALG) Ann Hematol 85 2006 366 373
3. A.K. Fielding, J.M. Rowe, and S.M. Richards et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993 Blood 113 2009 4489 4496
4. H. Pfeifer, B. Wassmann, and A. Pavlova et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) Blood 110 2007 727 734
5. A. Tanguy-Schmidt, P. Rousselot, and Y. Chalandon et al. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study Biol Blood Marrow Transplant 19 2013 150 155
6. R. Bassan, G. Rossi, and E.M. Pogliani et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00 J Clin Oncol 28 2010 3644 3652
7. Y. Chalandon, X. Thomas, and S. Hayette et al. Is less chemotherapy detrimental in adults with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) treated with high-dose imatinib? Results of the prospective randomized Graaph-2005 study Blood 120 2012 138 (ASH Annual Meeting Abstracts)
8. T.A. Gooley, W. Leisenring, J. Crowley, and B.E. Storer Estimation of failure probabilities in the presence of competing risks: new representations of old estimators Stat Med 18 1999 695 706
9. J.P. Fine, and R.J. Gray A proportional hazards model for subdistribution of a competing risk J Am Stat Assoc 94 1999 496 509
10. A.K. Fielding, and I. How Treat Philadelphia chromosome-positive acute lymphoblastic leukemia Blood 116 18 2010 3409 3417
11. D.A. Thomas, S. Faderl, and J. Cortes et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate Blood 103 2004 4396 4407
12. M. Yanada, J. Takeuchi, and I. Sugiura et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group J Clin Oncol 24 2006 460 466
13. K.H. Lee, J.H. Lee, and S.J. Choi et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia Leukemia 19 2005 1509 1516
14. B. Wassmann, H. Pfeifer, and N. Goekbuget et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) Blood 108 2006 1469 1477
15. A. de Labarthe, P. Rousselot, and F. Huguet-Rigal et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study Blood 109 2007 1408 1413
16. S. Giebel, B. Stella-Holowiecka, and M. Krawczyk-Kulis et al. Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL Bone Marrow Transplant 45 2010 1095 1101
17. A. Böhm, H. Herrmann, and G. Mitterbauer-Hohendanner et al. Stable non-transforming minimal residual disease in Philadelphia chromosome positive acute lymphoblastic leukemia after autologous transplantation: origin from neoplastic yet 'pre-leukemic' stem cells? Leuk Lymphoma 52 2011 842 848
18. M. Wetzler, D. Watson, and W. Stock et al. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation - results of CALGB 10001 (Alliance) Blood 120 2012 816 (ASH Annual Meeting Abstracts)
19. P. Kebriaei, R. Saliba, and G. Rondon et al. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes Biol Blood Marrow Transplant 18 2012 584 592
20. H. Chen, K.Y. Liu, and L.P. Xu et al. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia J Hematol Oncol 5 2012 29
21. M.G. Kiehl, L. Kraut, and R. Schwerdtfeger et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission J Clin Oncol 22 2004 2816 2825
22. S. Giebel, M. Labopin, and J. Holowiecki et al. Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years Ann Hematol 88 2009 1005 1013
23. N.C. Gorin, M. Labopin, and D. Blaise et al. Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission J Clin Oncol 27 2009 3987 3993